Head-to-head evidence
Topiramate (Topamax) vs Topiramate (Trokendi XR)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase · full Epilepsy pipeline
Topiramate (Topamax)
Marketed by Johnson & Johnson
NCT00266591 · Phase 3 · completed
The study was randomized and double-blind with 51 participants, and its primary endpoint was the clinical measure of time to withdrawal for therapeutic failure. However, the comparator arm is not identifiable in the available record and no primary-outcome results were posted, so the trial provides limited interpretable evidence.
Topiramate (Trokendi XR)
Marketed by Supernus Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Topiramate (Topamax)'s landscape · Topiramate (Trokendi XR)'s landscape